Arsenic trioxide (AT) has in vitro and in vivo radiosensitizing properties.
INTRODUCTION
Meta-iodobenzylguanidine (MIBG) is a guanethidine analog that is taken up via the noradrenaline transporter (NET) by neuroendocrine malignancies arising from sympathetic neuronal precursors (1). These neoplasms include neuroblastoma (NB), the commonest solid tumor of childhood which is often metastatic at diagnosis, and malignant paraganglioma/pheochromocytoma (MP). Recent therapeutic advances have led to modest improvements in the outcome of patients with high-risk NB; however approximately half of the patients with stage 4 NB and a much higher proportion of patients with relapsed or chemo-refractory disease succumb to it (2) . with a recommended dose of 0.15mg/kg/day. However, in children with NB and other solid tumors treated with AT as a single agent, dose-limiting toxicity was not encountered even at 0.25mg/kg/day when serum electrolytes were optimally maintained (clinicaltrials.gov identifier NCT00024258). Based on these preclinical and clinical data, and the nonoverlapping toxicities of the two agents, we hypothesized that AT would act as a radiosensitizer for MIBG therapy and conducted a pilot phase II study (NCT00107289) in patients with relapsed or refractory NB and MP, the results of which we report below.
PATIENT SELECTION
Patients > 1 year of age with high-risk NB (stage 4 disease diagnosed at >18 months of age or MYCN-amplified ≥ stage 3 tumor at any age), and a history of progressive disease (PD) or chemoresistance; and patients with MP <21 years of age were eligible. The presence of MIBG-avid evaluable or measurable disease ≥3 weeks after completion of systemic therapy was I-MIBG was administered in-patient only after demonstration of thyroid suppression as documented by sub-normal TSH levels. Urinary bladder protection was provided by maintenance of a Foley catheter for ≥72 hours after MIBG therapy. Radiation safety precautions were followed to minimize exposure to family, public and staff including use of isolation rooms and rolling lead shields. Patients were discharged only after the whole-body dose rate had fallen to <7cGy/h at a distance of 1m. AT was administered only if absolute QT interval was >500msec. During AT therapy, serum potassium and magnesium levels were maintained >4mEq/dL and >1.8mg/dL respectively. Filgrastim was given to maintain absolute neutrophil count (ANC) >500/µL. Platelet and red blood cell transfusions were administered as clinically indicated. Patients were required to receive autologous stem cell rescue (ASCR) if ANC remained <500/µL for >14 days despite filgrastim, if they required platelet transfusions > twice weekly for 4 weeks after MIBG therapy or if they experienced life-threatening infection in the setting of neutropenia.
Biostatistical Considerations
Since this was the first study of the novel combination of MIBG therapy and AT, we instituted early stopping rules for unacceptable toxicity: if ≥4 of the first 10 patients or 6 patients at any time experienced a ≥grade 3 non-hematologic toxic event or if ≥3 patients experienced graft failure after ASCR. The primary endpoint was efficacy of the combination as assessed by response. We proposed declaring treatment effective if probability of response was ≥0.4. A Simon two-stage design that differentiated between response rates of 0.4 and 0.65 was used with plans to treat 13 evaluable NB patients at maximal doses of 
Toxicities
Treatment was well tolerated in general without mortality or severe morbidity ( Table 2 ). None of the five patients treated with reduced doses of the treatment agents experienced severe adverse events and a further 14 patients received both agents at maximal doses. One patient (#6, 
Disease responses

NB
Overall, there were no major responses (CR+PR) observed in NB patients ( (Table 3 ). Three of the four patients with only soft-tissue disease prior to therapy had PD. Urine catecholamine levels were reduced in 4/7 patients with elevated levels.
MP
Both patients with MP had extensive skeletal disease (MIBG scores of 7 and 9, respectively) and one had measurable soft-tissue disease; neither had an objective response to MIBG+AT therapy. Urine normetanephrines decreased 50% in one patient, while the other did not secrete metanephrines.
The study was terminated after the first phase since it did not meet response criteria for continuation.
Post-protocol therapy and survival
Seventeen NB patients went on to receive additional therapy for their residual/PD after coming off study. Although ASCR was not indicated for any patient on study, 10 patients underwent ASCR after high-dose myelosuppressive (but non-myeloablative) chemotherapy after completing required protocol observations, and all engrafted post-ASCR. Other postprotocol therapies included immunotherapy with the anti-GD2 monoclonal antibody 3F8 (n=7). One patient had early PD and did not receive any further therapy while another did not receive any further therapy but is a long-term survivor >91 months after therapy despite having persistent MIBG-avid pancreatic disease. All patients were followed for late toxicities, none of which were observed. The contribution of MIBG+AT in prolonging survival could not be evaluated. Five-year overall survival (OS)
for NB patients is 37±11% with seven long-term survivors, all except one (#17, 
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Treatment of advanced neuroblastoma in children over 1 year of age: the AT not administered due to central-line induced arrhythmia; † MIBG-avid soft tissue disease only; ‡:continue to be progression-free; § 6/10 planned AT doses administered due to diarrhea and electrolyte imbalance
